文献速递眼底病与葡萄膜炎

证据提示肠道菌群失调在糖尿病视网膜病变中的作用

Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2022-01-01

本文综述过去5年文献,探讨糖尿病视网膜病变(DR)中肠道菌群失调的证据、肠-视网膜轴机制、对DR进展的预测价值及治疗靶点。糖尿病患者肠道菌群与无糖尿病者不同,DR患者与无DR者也不同,但后者差异较小;肠道菌群预测DR发生和进展的现有证据水平低。肠-视网膜轴可能成为延缓DR的靶点,但需调整饮食习惯的纵向区域研究。

要点

  • 糖尿病患者肠道菌群与无糖尿病者不同,DR患者与无DR者也不同,但后者差异较小。
  • 肠道菌群预测DR发生和进展的现有证据水平低。
  • 肠-视网膜轴可能成为延缓DR的靶点,但需调整饮食习惯的纵向区域研究。

核心结论

  • 研究肠道生态系统对糖尿病及其并发症如DR的治疗效用是一个新兴研究领域。
  • 肠-视网膜轴可能成为延缓DR的靶点,但需调整饮食习惯的纵向区域研究。

研究设计与样本

  • 综述过去5年发表的文献,使用预定关键词和文章。

主要发现

  • 糖尿病患者肠道菌群与无糖尿病者不同,DR患者肠道菌群与无DR者不同。
  • 糖尿病与无糖尿病之间的差异比糖尿病无DR与糖尿病有DR之间的差异更显著。
  • 早期研究提示肠-视网膜轴机制,但这些机制与已知的糖尿病患者肠道菌群变化无差异。
  • 当前关于肠道菌群对DR发生和进展预测价值的证据水平低。

临床怎么用

  • 靶向肠-视网膜轴的治疗途径包括生活方式改变、药理学抑制剂、益生菌和粪便微生物群移植。

局限性

  • 当前关于肠道菌群对DR发生和进展预测价值的证据水平低。
  • 肠-视网膜轴可能成为延缓DR的靶点,但需调整饮食习惯的纵向区域研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gut dysbiosis has been identified and tested in human trials for its role in diabetes mellitus (DM). The gut-retina axis could be a potential target for retardation of diabetic retinopathy (DR), a known complication of DM. This study reviews the evidence suggesting gut dysbiosis in DR. METHODS: The published literature in the past 5 years was reviewed using predetermined keywords and articles. The review intended to determine changes in gut microbiome in DR, the hypothesized mechanisms linking to the gut-retina axis, its predictive potential for progression of DR, and the possible therapeutic targets. RESULTS: The gut microbiota of people with DM differ from those without it, and the gut microbiota of people with DR differ from those without it. The difference is more significant in the former (DM versus no DM) and less significant in the latter (DM without DR versus DM with DR). Early research has suggested mechanisms of the gut-retina axis, but these are not different from known changes in the gut microbiome of people with DM. The current evidence on the predictive value of the gut microbiome in the occurrence and progression of DR is low. Therapeutic avenues targeting the gut-retina axis include lifestyle changes, pharmacologic inhibitors, probiotics, and fecal microbiota transplantation. CONCLUSIONS: Investigating the therapeutic utility of the gut ecosystem for DM and its complications like DR is an emerging area of research. The gut-retina axis could be a target for retardation of DR but needs longitudinal regional studies adjusting for dietary habits.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Thakur PS, Aggarwal D, Takkar B, et al. Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2022. PMID: 35877085. doi:10.1167/iovs.63.8.21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。